Клинико-лабораторная оценка овариального резерва с позиции репродуктолога

1. Tal R., Seifer D.B. Ovarian reserve testing: a user’s guide. Am. J. Obstet. Gynecol. 2017; 217(2): 129-40.

2. Шамилова Н.Н. Клинико-прогностическое значение молекулярно-биологических маркеров при преждевременной недостаточности яичников: дисс. … канд. мед. наук. М.; 2009. 202с.

3. Wallace W.H., Kelsey T.W. Human ovarian reserve from conception to the menopause. PLoS One. 2010; 5(1): e8772.

4. Боярский К.Ю., Гайдуков С.Н., Чинчаладзе А.С. Факторы, определяющие овариальный резерв. Журнал акушерства и женских болезней. 2009; 58(2): 65-71.

5. Буренкова Н.Б., Комличенко Э.В., Иванов А.В. Проблема выбора тактики лечения женщин со сниженным овариальным резервом. Репродуктивная медицина. 2014; 3-4: 28-33.

6. Тотчиев Г.Ф., Котиков Н.П., Семятов С.Д., Токтар Л.Р. Менопауза. Современные аспекты прогнозирования. Вестник Российского университета дружбы народов. Серия: Медицина. 2012; 5: 494-9.

7. Позднякова А.А., Жахур Н.А., Ганичкина М.Б., Марченко Л.А. Новое в лечении бесплодия при преждевременной недостаточности яичников. Акушерство и гинекология. 2015; 7: 26-32.

8. Филиппова Е.С., Козаченко И.Ф., Быков А.Г., Бобров М.Ю., Адамян Л.В. Современный взгляд на овариальный резерв у женщин репродуктивного возраста с эндометриоидными кистами яичников (обзор литературы). Проблемы репродукции. 2017; 23(2): 72-80.

9. Gingold J.A., Lee J.A., Whitehouse M.C., Rodriguez-Purata J., Sandler B., Grunfeld L. et al. Maximum basal FSH predicts reproductive outcome better than cycle specific basal FSH levels: waiting for”better” month conveys limited retrieval benefits. Reprod. Biol. Endocrinol. 2015; 13: 91.

10. Jayaprakasan K., Campbell B., Hopkisson J., Clewes J., Johnson I., Raine-Fenning N. Establishing the intercycle variability of three-dimensional ultrasonographic predictors of ovarian reserve. Fertil. Steril. 2008;90(6): 2126-32.

11. Esposito M.A., Coutifaris C., Barnhart K.T. A moderately elevated day 3 FSH concentration has limited predictive value, especially in younger women. Hum. Reprod. 2002; 17(1): 118-23.

12. Broekmans F.J., Kwee J., Hendriks D.J., Mol B.W., Lambalk C.B. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum. Reprod. Update. 2006; 12(6): 685-718.

13. Roberts J.E., Spandorfer S., Fasouliotis S.J., Kashyap S., Rosenwaks Z. Taking a basal follicle-stimulating hormone history is essential before initiating in vitro fertilization. Fertil. Steril. 2005; 83(1): 37-41.

14. Kim C., Slaughter J.C., Wang E.T., Appiah D., Schreiner P., Leader B. et al. Anti-Müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years. Maturitas. 2017; 102: 18-25.

15. La Marca A., Sighinolfi G., Radi D., Argento C., Baraldi E., Artenisio A.C. et al. Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum. Reprod. Update. 2010; 16(2): 113-30.

16. Durlinger A.L., Gruijters M.J., Kramer P., Karels B., Kumar T.R., Matzuk M.M. et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001; 142(11): 4891-9.

17. Garcia-Velasco J.A., Moreno L., Pacheco A., Guillén A., Duque L., Requena A., Pellicer A. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil. Steril. 2005; 84(1): 82-7.

18. Grossman M.P., Nakajima S.T., Fallat M.E., Siow Y. Müllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil. Steril. 2008; 89(5, Suppl.): 1364-70.

19. Wiweko B., Prawesti D.M., Hestiantoro A., Sumapraja K., Natadisastra M., Baziad A. Chronological age vs biological age: an age-related normogram for antral follicle count, FSH and anti-Mullerian hormone. J. Assist. Reprod. Genet. 2013; 30(12): 1563-7.

20. Venturella R., Lico D., Sarica A., Falbo M.P., Gulletta E., Morelli M. et al. OvAge: a new methodology to quantify ovarian reserve combining clinical, biochemical and 3D-ultrasonographic parameters. J. Ovarian Res. 2015; 8: 21.

21. Gleicher N., Weghofer A., Barad D.H. Defining ovarian reserve to better understand ovarian aging. Reprod. Biol. Endocrinol. 2011; 9: 23.

22. Steiner A.Z., Herring A.H., Kesner J.S., Meadows J.W., Stanczyk F.Z., Hoberman S., Baird D.D. Antimüllerian hormone as a predictor of natural fecundability in women aged 30-42 years. Obstet. Gynecol. 2011;117(4): 798-804.

23. Hagen C.P., Vestergaard S., Juul A., Skakkebæk N.E., Andersson A.M., Main K.M. et al. Low concentration of circulating antimüllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertil. Steril. 2012; 98(6): 1602-8. e2.

24. Tal R., Tal O., Seifer B.J., Seifer D.B. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertil. Steril. 2015; 103(1): 119-30. e3.

25. Broer S.L., Mol B.W., Hendriks D., Broekmans F.J. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil. Steril. 2009; 91(3): 705-14.

26. Seifer D.B., Tal O., Wantman E., Edul P., Baker V.L. Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013. Fertil. Steril. 2016; 105(2): 385-93. e3.

27. Leader B., Hegde A., Baca Q., Stone K., Lannon B., Seifer D.B. et al. High frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers. Fertil. Steril. 2012;98(4): 1037-42.

28. Fanchin R., Taieb J., Lozano D.H., Ducot B., Frydman R., Bouyer J. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum. Reprod. 2005. 20(4): 923-7.

29. van Disseldorp J., Lambalk C.B., Kwee J., Looman C.W., Eijkemans M.J., Fauser B.C. et al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum. Reprod. 2010; 25(1): 221-7.

30. Kissell K.A., Danaher M.R., Schisterman E.F., Wactawski-Wende J., Ahrens K.A., Schliep K. et al. Biological variability in serum anti-Mullerian hormone throughout the menstrual cycle in ovulatory and sporadic anovulatory cycles in eumenorrheic women. Hum. Reprod. 2014; 29(8): 1764-72.

31. Deeks E.D. Elecsys(®) AMH assay: a review in anti-Müllerian hormone quantification and assessment of ovarian reserve. Mol. Diagn. Ther. 2015; 19(4): 245-9.

32. van den Berg M.H., van Dulmen-den Broeder E., Overbeek A., Twisk J.W., Schats R., van Leeuwen F.E. et al. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. Hum. Reprod. 2010; 25(6): 1520-7.

33. Plante B.J., Cooper G.S., Baird D.D., Steiner A.Z. The impact of smoking on antimullerian hormone levels in women aged 38 to 50 years. Menopause. 2010; 17(3): 571-6.

34. Jaiswar S.P., Natu S.M., Sujata, Sankhwar P.L., Manjari G. Prediction of poor ovarian response by biochemical and biophysical markers: a logistic regression model. J. Obstet. Gynaecol. India. 2015; 65(6): 411-6.

35. Christianson M.S., Shoham G., Tobler K.J., Zhao Y., Cordeiro C.N., Leong M., Shoham Z. Measurement of antral follicle count in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey. J. Assist. Reprod. Genet. 2015; 32(10): 1435-40.

36. Штадмауэр Л.А., Тур-Каспа А., ред. Ультразвуковая диагностика в репродуктивной медицине. Достижения в обследовании и лечении бесплодия и вспомогательных репродуктивных технологиях. Пер. с англ. Гус А.И., перевод, ред. М.: ГЭОТАР-Медиа; 2017. 488с. 

37. Baker T.G. A quantitative and cytological study of germ cells in human ovaries. Proc. R Soc. Lond. B Biol. Sci. 1963; 158: 417-33.

38. Pastore L.M., Christianson M.S., Stelling J., Kearns W.G., Segars J.H. Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POF, POR, and FOR. J. Assist. Reprod. Genet. 2018; 35(1): 17-23.

39. Gleicher N., Kushnir V.A., Weghofer A., Barad D.H. The importance of adrenal hypoandrogenism in infertile women with low functional ovarian reserve: a case study of associated adrenal insufficiency. Reprod. Biol. Endocrinol. 2016; 14: 23.

40. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. Webber L., Davies M., Anderson R., Bartlett J., Braat D., Cartwright B. et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 2016; 31(5): 926-37.

41. Cohen J., Chabbert-Buffet N., Darai E. Diminished ovarian reserve, premature ovarian failure, poor ovarian responder - a plea for universal definitions. J. Assist. Reprod. Genet. 2015; 32(12): 1709-12.

42. Nelson S.M., Klein B.M., Arce J.-C. Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials. Fertil. Steril. 2015; 103(4): 923-30. e1.

Поступила 21.11.2017

Принята в печать 22.12.2017